|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By intersecting differentially expressed genes in EHP-101-treated mice with a dataset of human scleroderma intrinsic genes, 53 overlapped genes were discovered, including biomarkers of SSc like the C-C motif chemokine 2 (Ccl2) and the interleukin 13 receptor subunit alpha 1 (IL-13Ra1) genes.
|
30076848 |
2018 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Stretching also reduced the expression of CCL2 and ADAM8 in the skin at week 4, which are two genes known to be upregulated in both murine sclGvHD and the inflammatory subset of human SSc.
|
28261202 |
2017 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Higher CCL2 levels in the circulation were predictive of ILD progression and poorer survival in patients with early SSc, findings that support the notion that CCL2 has a role as a biomarker and potential therapeutic target.
|
28575534 |
2017 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging pieces of evidence indicate that the CCL2/CCR2 axis is involved in fibrotic diseases, such as increased plasma levels of CCL2 and the presence of CCL2-hyperresponsive fibroblasts explanted from patients with systemic sclerosis and idiopathic pulmonary fibrosis.
|
24583146 |
2014 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the transcript profile of sclerodermatous graft-versus-host disease (sclGVHD) mice resembles the skin transcriptomes of a subgroup of SSc patientswith IL13/IL4-inducible skin signature wherein the profibrotic chemokine CCL2 plays a key role.
|
24061076 |
2013 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunofluorescence staining revealed that SELP and CCL2 were also overexpressed in affected skin and lung tissue from SSc patients compared to those from controls.
|
23897225 |
2013 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study shows that the increased number of macrophages with heterogeneous immunophenotypes, which might be induced by MCP-1 and CSF-1, could participate in the sclerotic lesion formation, presumably through increased fibrogenic factors such as galectin-3 and TGF-β1; the data may provide useful information to understand the pathogenesis of the human scleroderma condition.
|
22700848 |
2013 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Meta-analyses failed to reveal an association between SSc and CTLA-4 -1722 C/T, MCP-1 -2518 A/G polymorphisms.
|
23782302 |
2013 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets.
|
22245215 |
2012 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results demonstrate that the functional variant -2518A>G of CCL2 is not implicated in the susceptibility or phenotype of SSc.
|
19032966 |
2009 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MCP-1 -2518 A/G single nucleotide polymorphism in Slovak patients with systemic sclerosis.
|
18528529 |
2008 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms within CCL2 gene are associated with susceptibility neither to SSc nor to specific disease phenotypes.
|
18381789 |
2008 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, basal as well as TNF-induced MCP-1 expression of fibroblasts isolated from a GG-homozygote SSc patient was significantly higher than MCP-1 expression of fibroblasts isolated from heterozygote or AA-homozygote donors.
|
15654958 |
2005 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Results of immunohistochemistry revealed that MCP-1 was expressed in keratinocytes, infiltrating inflammatory cells, fibroblasts, and endothelial cells in scleroderma skin, whereas normal control skin showed no MCP-1 expression.
|
15654958 |
2005 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review summarizes recent findings of the potential roles of CCL2 in cutaneous sclerosis in experimental animal models of scleroderma as well as human scleroderma.
|
12846061 |
2003 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated the expression of MCP-1 mRNA in infiltrating mononuclear cells and keratinocytes in scleroderma and contact dermatitis skin.
|
11378330 |
2001 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MCP-1 expression in SSc skin sections was studied by immunohistochemistry.
|
11407698 |
2001 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To identify possible stimulators of MCP-1 overexpression in SSc lesions, cultured dermal fibroblasts were incubated with recombinant platelet-derived growth factor (PDGF) and analyzed by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay.
|
11710722 |
2001 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, increased responsiveness of scleroderma fibroblasts to MCP-1 could result in a continuation of the fibrotic response.
|
11592069 |
2001 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, MCP-1, MIP-1alpha and MIP-1beta may be involved in the disease process, possibly by augmenting leucocyte migration into the affected tissues in SSc.
|
10403930 |
1999 |